Year-to-date obesity drug sales at Novo Nordisk surpass all of 2020

Novo Nordisk obesity drugs Saxenda and Wegovy have sold for DKK 5.9bn (USD 919m) in the first three quarters of the year, surpassing the full-year sales last year.
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Sales of Novo Nordisk's obesity drugs have continued their upward momentum, Wednesday's quarterly report from the pharmaceutical company shows.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading